Skip to Main Content
Oncology CRO Services
Full Service CRO
Clinical Analytics
Site Network
Consulting
Development Phase
Preclinical Preclinical and clinical research planning helps you bring forward the best emerging science to improve cancer diagnosis and treatment.
Early Phase Research Catalyst Oncology, an oncology clinical research organization, works with innovative biotechs on a range of early phase study designs and therapies.
Late Phase Research Catalyst Oncology helps move oncology therapies through the complex and dynamic clinical trial environment with workable solutions, best-in-class technologies, and a data-centric approach.
Case Study
Immuno-Oncology
Helping to bring immunotherapies to cancer patients in need
Read more
Insights
Contact Us
Oncology CRO Services
Full Service CRO
Clinical Analytics
Site Network
Consulting
Development Phase
PreclinicalPreclinical and clinical research planning helps you bring forward the best emerging science to improve cancer diagnosis and treatment.
Early Phase ResearchCatalyst Oncology, an oncology clinical research organization, works with innovative biotechs on a range of early phase study designs and therapies.
Late Phase ResearchCatalyst Oncology helps move oncology therapies through the complex and dynamic clinical trial environment with workable solutions, best-in-class technologies, and a data-centric approach.
Case Study
Immuno-Oncology
Helping to bring immunotherapies to cancer patients in need
Read more
Insights
Contact Us
Category: Antibody drug conjugate
Logo of the World ADC conference Article Key Takeaways from World ADC 2024 The resurgence of ADCs in cancer therapy The World ADC conference is the leading conference Read Now Exterior of the ESMO conference Blog Highlights of ESMO 2024 Recent Advances in Oncology Drug Development I was honored, along with my Catalyst Oncology colleagues, Read Now Hallway at 2024 ASCO, McCormick Place, Chicago Blog Highlights of ASCO 2024 Cancer Drug Development and Trends It is hard to imagine that it has only been Read Now Blog Highlights of ESMO 2023: The year of ADCs Insights from the annual oncology conference By Andrew Zupnick, PhD, Vice President of Oncology Drug Read Now